These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36634085)

  • 21. Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies.
    Bavishi C; Whelton PK; Mancia G; Corrao G; Messerli FH
    J Hypertens; 2021 Apr; 39(4):784-794. PubMed ID: 33560054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study.
    Shams E; Kamalumpundi V; Cheng L; Taiwo A; Shibli-Rahhal A; Dokun AO; Correia MLG
    Arq Bras Cardiol; 2023 Mar; 120(4):e20220277. PubMed ID: 37098985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ACEI and ARB on COVID-19 patients: A meta-analysis.
    Xue Y; Sun S; Cai J; Zeng L; Wang S; Wang S; Li J; Sun L; Huo J
    J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320981321. PubMed ID: 33325306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.
    Oussalah A; Gleye S; Clerc Urmes I; Laugel E; Callet J; Barbé F; Orlowski S; Malaplate C; Aimone-Gastin I; Caillierez BM; Merten M; Jeannesson E; Kormann R; Olivier JL; Rodriguez-Guéant RM; Namour F; Bevilacqua S; Losser MR; Levy B; Kimmoun A; Gibot S; Thilly N; Frimat L; Schvoerer E; Guéant JL
    Clin Infect Dis; 2020 Dec; 71(9):2447-2456. PubMed ID: 32623470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
    Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
    Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
    de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
    BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
    Lebek S; Tafelmeier M; Messmann R; Provaznik Z; Schmid C; Maier LS; Birner C; Arzt M; Wagner S
    Eur J Heart Fail; 2020 Dec; 22(12):2248-2257. PubMed ID: 33017071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension.
    Kuzeytemiz M; Tenekecioglu E
    J Investig Med; 2022 Mar; 70(3):786-791. PubMed ID: 34987107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis.
    Asiimwe IG; Pushpakom S; Turner RM; Kolamunnage-Dona R; Jorgensen AL; Pirmohamed M
    Br J Clin Pharmacol; 2021 Dec; 87(12):4534-4545. PubMed ID: 34101232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
    Choksi TT; Zhang H; Chen T; Malhotra N
    Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.
    Yin J; Wang C; Song X; Li X; Miao M
    Am J Hypertens; 2022 May; 35(5):462-469. PubMed ID: 35512430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
    JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis.
    Lee HW; Yoon CH; Jang EJ; Lee CH
    Thorax; 2021 May; 76(5):479-486. PubMed ID: 33504565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACEi/ ARB and Deaths of COVID-19 Patients.
    Azad GN; Kumar A
    Curr Hypertens Rev; 2022; 18(2):158-162. PubMed ID: 35392786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.
    Chu C; Zeng S; Hasan AA; Hocher CF; Krämer BK; Hocher B
    Br J Clin Pharmacol; 2021 Jun; 87(6):2475-2492. PubMed ID: 33217033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.
    Armstrong K; Soltoff A; Rieu-Werden M; Metlay J; Haas J
    PLoS One; 2021; 16(3):e0247548. PubMed ID: 33651840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
    Rico-Mesa JS; White A; Anderson AS
    Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients.
    Baslilar S; Saylan B
    Ann Saudi Med; 2021; 41(5):268-273. PubMed ID: 34618609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.